ReviewMicromachines2022
Advanced MXene-Based Micro- and Nanosystems for Targeted Drug Delivery in Cancer Therapy.
Review in Micromachines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- NbRSC advances · 2026Article
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Biocompatibility and immunomodulation of MXenes for targeted delivery of bioactive agents and drugs.Bioactive materials · 2026Review
- MXenes in diabetes: diagnostic and therapeutic applications.RSC advances · 2025Review
- Theranostic potential of MXene-based platforms for dual MiRNA targeting in metastatic bladder cancer.Cancer cell international · 2025Review
- MXenes as emerging materials to repair electroactive tissues and organs.Bioactive materials · 2025Review
- Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy.Materials (Basel, Switzerland) · 2025Review
- MXene and prostate cancer: is there promising news?Nanomedicine (London, England) · 2025Review
- Recent Trends in Biomedical Applications of CuInternational journal of nanomedicine · 2025Review
- MXene-Mediated Nanocarrier Delivery Enhances the Chondroprotective Effects of Quercetin in Experimental Osteoarthritis.International journal of nanomedicine · 2025Article
- MXene: A wonderful nanomaterial in antibacterial.Frontiers in bioengineering and biotechnology · 2024Review
- MXenes-polymer nanocomposites for biomedical applications: fundamentals and future perspectives.Frontiers in chemistry · 2024Review
- Environmental implications of metal-organic frameworks and MXenes in biomedical applications: a perspective.RSC advances · 2023Review
- Electrospun Nanofibers: Shaping the Future of Controlled and Responsive Drug Delivery.Materials (Basel, Switzerland) · 2023Review
- MXene-Carbon Nanotube Composites: Properties and Applications.Nanomaterials (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MXenes with unique mechanical, optical, electronic, and thermal properties along with a specific large surface area for surface functionalization/modification, high electrical conductivity, magnetic properties, biocompatibility, and low toxicity have been explored as attractive candidates for the targeted delivery of drugs in cancer therapy. These two-dimensional materials have garnered much attention in the field of cancer therapy since they have shown suitable photothermal effects, biocompatibility, and luminescence properties. However, outstanding challenging issues regarding their pharmacokinetics, biosafety, targeting properties, optimized functionalization, synthesis/reaction conditions, and clinical translational studies still need to be addressed. Herein, recent advances and upcoming challenges in the design of advanced targeted drug delivery micro- and nanosystems in cancer therapy using MXenes have been discussed to motivate researchers to further investigate this field of science.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.